retatrutide ada 2025 results Phase 3: 60% Achieved Surgical-Level Weight Loss ADA 2026 confirmed what many

The scientists behind these discoveries could be among the 2025 Nobel Prize winners.

Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

In a recent regulatory shift, the FDA has ended the allowance for compounding pharmacies to produce copycat versions of popular GLP-1 receptor agonists

While the world has focused on the battle between injectables and oral tablets, the "Mucosal Frontier" addresses the three biggest hurdles in peptide therapy: 1 Bioavailability: By utilizing a mucosal delivery platform, the drug avoids first-pass metabolism in the liver, potentially offering a more efficient way for the body to utilize the peptide compared to traditional oral versions

(12 kg)

Hims & Hers Health runs a telehealth and consumer wellness platform that connects patients with...